HSG Blog

Thank you to Teva Pharmaceuticals

HD Insights thanks Teva for its ongoing support Teva CNS is committed to continued research and development of its product portfolio...

Highlights of HSG 2016: Discovering Our Future

The Huntington Study Group held its 23rd Annual Meeting and 10th Annual Clinical Research Symposium November 2-5, in Nashville, TN....

Thank you to Raptor

Thank you to Raptor

HD Insights thanks raptor for its generous support.

Editor’s Letter

Welcome to the 16th edition of HD Insights, timed for release at the beginning of the first Pan-American Parkinson’s Disease...

Job Opportunity: Deputy Editor, HD Insights

Job description: If you are passionate about HD research and want to reach nearly 3,000 HD researchers and clinicians around...

HD Insights Volume 15 (PDF)

To read a non-PDF version of HD Insights Vol. 15, click here.

Finding balance in HD: The role of PIAS1 in protein homeostasis

By: Joseph Ochaba, PhD There are currently no medications or treatments to alter the devastating course of HD. Although some...

Meet the Company: WAVE Life Sciences

Meet the Company: WAVE Life Sciences

VITAL SIGNSName: WAVE Life SciencesStock symbol: WVEShare price as of 10/9/16: $30.27Market capitalization: $574 millionU.S. Headquarters: Cambridge, MA Precision Medicine...

Meet the Compounds: WVE-120101 and WVE-120102

By: Meredith A. Achey, BMManufacturer: WAVE Life SciencesMolecular formula: Stereopure antisense oligonucleotide (ASO) targeting single nucleotide polymorphisms (SNPs).Mechanism of action:...

Highlights from the Journal of Huntington’s Disease

Induced pluripotent stem cells in HD researchBy: Kimberly Kegel-Gleason, PhDOriginal article: Tousley A, Kegel-Gleason KB. Induced Pluripotent Stem Cells in...

1 2 3 4 5 20